Based on its recent analysis of the device biologics market, Frost & Sullivan recognizes ApaTech with the 2009 North American Frost & Sullivan Company of the Year Award. The device biologics market is one of the most lucrative in the medical device industry. Though relatively new, the field has already experienced periods of breakthrough innovation as evidenced in ApaTech’s products.
Cutting edge research by ApaTech has introduced the revolutionary new class of bone graft substitute called Actifuse, which is based on silicated calcium phosphate. This development is a definitive factor in the growth and success of this company, which is driven by a commitment to the progress of orthopedic biologics. ApaTech has achieved this through clear product differentiation strategies and sound marketing tactics, addressing key market issues.
“ApaTech is set to build on a very strong base it has established in the advanced geographies, and as cash-rich medical markets increase, revenue growth and consolidation of market share are inevitable,” says Frost & Sullivan Industry Analyst, Aarti Shetty.
Traditional autogenous grafts, or autografts, were widely considered the “gold standard” among bone graft materials. Despite the material being transplanted from the same individual, complications and pain at the affected site have been common. The clinical effectiveness of autografts is considered the primary reason for their wide acceptance. But improved synthetic materials treated with sophisticated methods for increasing biological activity, have the added advantage of avoiding a secondary procedure, and considerably eliminating the risks involved with surgery. In particular calcium phosphates have emerged as the alternative of choice, due to their ability to closely mimic bone characteristics in terms of chemical nature and structural stability.